One RCT [26] conducted by van Bommel et al. investigated an SGLT2 inhibitor, which involved 24 T2D patients who underwent treatment with dapagliflozin (10 mg/day) for 12 weeks. Here, SLC5A2 is linked to type 2 diabetes mellitus.